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Abstract
The CXCL12c chemokine arises by alternative splicing from Cxcl12, an essential gene during development. This protein
binds CXCR4 and displays an exceptional degree of conservation (99%) in mammals. CXCL12c is formed by a protein core
shared by all CXCL12 isoforms, extended by a highly cationic carboxy-terminal (C-ter) domain that encompass four
overlapped BBXB heparan sulfate (HS)-binding motifs. We hypothesize that this unusual domain could critically determine
the biological properties of CXCL12c through its interaction to, and regulation by extracellular glycosaminoglycans (GAG)
and HS in particular. By both RT-PCR and immunohistochemistry, we mapped the localization of CXCL12c both in mouse
and human tissues, where it showed discrete differential expression. As an unprecedented feature among chemokines, the
secreted CXCL12c strongly interacted with cell membrane GAG, thus remaining mostly adsorbed on the plasmatic
membrane upon secretion. Affinity chromatography and surface plasmon resonance allowed us to determine for CXCL12c
one of the higher affinity for HS (Kd=0.9 nM) ever reported for a protein. This property relies in the presence of four
canonical HS-binding sites located at the C-ter domain but requires the collaboration of a HS-binding site located in the
core of the protein. Interestingly, and despite reduced agonist potency on CXCR4, the sustained binding of CXCL12c to HS
enabled it to promote in vivo intraperitoneal leukocyte accumulation and angiogenesis in matrigel plugs with much higher
efficiency than CXCL12a. In good agreement, mutant CXCL12c chemokines selectively devoid of HS-binding capacity failed
to promote in vivo significant cell recruitment. We conclude that CXCL12c features unique structural and functional
properties among chemokines which rely on the presence of a distinctive C-ter domain. The unsurpassed capacity to bind
to HS on the extracellular matrix would make CXCL12c the paradigm of haptotactic proteins, which regulate essential
homeostatic functions by promoting directional migration and selective tissue homing of cells.
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Introduction
The CXC chemokine, stromal cell-derived factor 1/CXCL12
[1] is a constitutive and broadly expressed chemokine that exerts
its functions through the G-protein coupled receptor (GPCR)
CXCR4 [2]. Recently, a novel receptor for CXCL12, RDC-1/
CXCR7, has been identified [3–5]. Mouse and human
CXCL12a, the major CXCL12 isoform, differ by a single,
homologous substitution (Val18 to Ile18) [1,6] and each protein
owns the capacity to bind and activate the orthologue CXCR4
receptor. The exceptional conservation of both CXCR4 and
CXCL12 structure and function in mammalians announces the
essential roles played by this singular couple. CXCL12 is unique
among the family of chemokines as it plays non-redundant roles
during embryo life in the development of both cardiovascular [7]
and central nervous system [8,9], hematopoiesis [10] and
colonization of the gonads by primordial germ cells [11]. In the
post-natal life, CXCL12 is involved in trans-endothelial migration
of leukocytes [12–15] and regulates critically both the homing and
egress of CD34+CXCR4+progenitor cells from the bone marrow,
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plays a prominent role in physiopathological processes such as
inflammation [17], angiogenesis and wound healing [18,19].
Moreover, CXCL12 is a critical factor for growth, survival and
metastatic dissemination of a number of tumors [20].
The engagement of CXCR4 by CXCL12 triggers the activation
of heterotrimeric Gabc-proteins, which ultimately promote the
directional migration of cells towards a concentration gradient of
ligand that defines the haptotactic function of chemokines. In vivo,
chemokines are believed to form gradient concentrations by
binding to glycosaminoglycans (GAG), the glycanic moieties of
proteoglycans, and in particular to heparan sulfate (HS).
Electrostatic contacts between the negatively charged HS and
basic residues exposed at the surface of chemokines, along with
structural features of the oligosaccharide, determine both the
affinity and the specificity of the molecular interactions that are
supposed to modulate the in vivo biological activity of chemokines
complexed to proteoglycans [21–24].
The study of the well characterized CXCL12a isoform provided
most of the knowledge of CXCL12 biological properties including
interaction with GAG, which is essentially accounted for by a
canonical BBXB (B for basic amino-acids, X any other amino-
acid) HS-binding motif, located in the first b-strand of the protein
[25]. In contrast, the novel CXCL12c isoform remains largely
unexplored regarding protein expression and biological function.
CXCL12c is formed by a core domain encompassing the 68
amino-acids of the major CXCL12a isoform shared with all
CXCL12 proteins, which is extended by a carboxy-terminal (C-
ter) domain. This region, highly-enriched in basic amino-acids,
encodes four overlapped HS-binding motifs and shows identical
sequence in human, rat and mouse species [6,26,27]. This
positively charged domain enables CXCL12c with an amazing
capacity to interact with GAG [28]. We speculated that this
property might be determinant in defining the in vivo capacity of
this peculiar chemokine to promote both migration and homing of
cells in tissues. In this work we characterized CXCL12c tissue
expression and the capacity of this isoform to interact with
CXCR4 and promote cell migration in vitro. Moreover, we
investigated the interaction of CXCL12c with GAG both in vitro
and on intact cells. Finally, we assessed the functionality of this
novel isoform in vivo. Our findings indicate that CXCL12c displays
a sustained binding on GAG and exhibits a prolonged chemokine
activity in vivo that makes it a paradigm among haptotactic
proteins. The intacteness of the BBXB sites in the distinctive
CXCL12c C-ter domain critically determine the biological activity
of the chemokine.
Results
Tissue distribution of Cxcl12c products
The Cxcl12c isoform cDNA was obtained from BALB/c mouse
brain mRNA. The isolated cDNA nucleotide sequence was
identical to the previously reported murine Cxcl12c isoform
(GenBank NCBI accession number NM_001012477) that encodes
the CXCL12c protein (thereafter called c-wt for the recombinant
and chemically synthesized proteins, GenPept NCBI accession
number NP_001012495). The expression of the c-wt mRNA and
protein in embryo and adult mouse tissues and in human adult
tissues was investigated by RT-PCR and immunohistochemistry
(Figure 1C–E) using a novel monoclonal antibody (mAb) (6E9)
that recognizes selectively a c-wt C-ter epitope encompassing the
sequence K78/K80 (Figure 1A–B). The c-wt protein expression
was compared to these of other isoforms detected by the well
characterized K15C mAb, which recognizes an amino-terminal
(N-ter) -encoded epitope shared by all the CXCL12 isoforms
[29,30].
In adult mice, the Cxcl12c mRNA was poorly expressed in liver,
intestine and kidney, contrasting with the abundant expression of
Cxcl12a mRNA (Figure 1C). Regarding the protein (Figure 1D), c-
wt was undetectable in bladder muscular and mucosa layers, while
in the intestinal tract, a faint and discontinuous immunostaining
was restricted to the mucosa and excludes the muscular layer
(Figure 1Diii). Cxcl12c mRNA was abundant in brain, heart
(Figure 1C) and bone marrow, where it was expressed as a
predominant isoform akin to Cxcl12a as quantified by real time
PCR (Figure 1E). c-wt protein was detected in cardiac muscle,
valves and large vessels (Figure 1Di). In lungs, Cxcl12c mRNA
expression was barely detected in the adult (Figure 1C). Interest-
ingly, a detailed analysis of c-wt expression in mouse embryos
showed that while the protein was virtually absent from trachea
and large bronchia, it accumulated in the bronchioli (Figure 1Dii).
The c-wt protein was consistently detected in mesothelial tissues
such as peritoneum (Figure 1Diii) and pleura (data not shown). Of
note, c-wt was detected in endothelia of large and small vessels
both in human and mouse (Figure 1Div-v), and in fibroblasts
either of human skin (data not shown) or synovial inflammatory
tissue (rheumatoid arthritis; Figure 1Dv).
c-wt binds to immobilized and cell surface HS with high
affinity
Previously it has been shown that the CXCL12a protein (a-wt)
binds with high affinity to HS [31] both in vitro and in intact cells
through specific interaction with the canonical HS-binding motif
(K24H25L26K27) located in the core of the protein shared by all
the CXCL12 isoforms. Mutation of this motif (K24S/K27S) fully
prevents binding to HS without affecting neither the overall
structure nor the capacity of the mutant chemokine (a-m) to bind
and activate CXCR4 [31]. The specific C-ter domain of the c-wt
isoform presents a marked basic character, with a 60% of the
residues being positively charged and clustered in 4 overlapped
HS-binding sites. This prompted us to investigate the c-wt/GAG
interactions both in vitro and on intact cells. Analysis performed
with chemically synthesized chemokines, showed that c-wt isoform
required 1.01 M NaCl to be eluted from a heparin (HP)-affinity
column (Figure 2B) as compared to 0.59 M required for elution of
a-wt. Chemically synthesized c-wt C-ter peptide encompassing
amino-acids 69 to 98 of the corresponding c-wt protein required
0.88 M NaCl to be eluted, indicating that this domain interacts
with HP per se with high affinity and might contributes to the
strong interaction with HP displayed by c-wt. In good agreement,
neutralization of positively charged amino-acids by mutation of
the C-ter BBXB motifs either in the c-wt (c-m1, Figure 2A) or the
isolated C-ter peptides (C-ter c-m1 and C-ter c-m2, Figure 2A),
reduced drastically the ionic force (0.69, 0.5 and 0.28 M NaCl,
respectively, Figure 2B) required for their elution from the HP-
affinity column.
Surface plasmon resonance (SPR) experiments (Figure 2C)
confirmed that c-wt interacts with HP with unprecedented high
affinity (Kd=0.9 nM). Furthermore, they showed that the
interaction with the oligosaccharide was severely impaired in the
mutant c-m1 (Kd=10.4 nM), thus proving the important
contribution of the C-ter domain BBXB sites to the binding on
HP. Both HP-affinity chromatography and SPR experiments
(Figure 2B–C) proved that the c-m2 mutant (Figure 2A), which
lacks all functional BBXB motifs, was virtually devoid of the
capacity to interact with HP.
Recognition of CXCL12 proteins by the K15C mAb is not
masked by their interaction with GAG [23]. Using this mAb, we
CXCL12c-HS. In Vivo Functions
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cells was greatly increased for c-wt as compared to a-wt
(Figure 3A). Of note, and of particular biological relevance, we
found that c-wt also binds onto primary, human-microvascular
endothelial cells (HMVEC) with the highest efficiency as
compared to a-wt (Figure 3B). It is interesting to note that while
the c-m1 mutant protein retained the capacity to bind on CHO-
K1 parental cells, this capacity was notably decreased in HMVEC,
Figure 1. Tissue expression of c-wt in human and mouse. (A) Specific immunofluorescent detection of c-wt. HEK-293T cells were transfected
either with b-wt- (upper panel) or c-wt- (lower panel) expressing pCDNA3.1 plasmids, treated with Brefeldin A, permeabilised with saponin and
labelled with the 6E9 mAb and a Texas Red anti-mouse IgG. The nuclei of cells were counterstained with DAPI. Images are representative of six
independent determinations. Original magnification663. (B) Mutagenesis of K78/K80 in c-wt C9 (c-C9
up) prevents the specific recognition of the c-wt
chemokine by the 6E9 mAb. Western blot analysis of chemically synthesized a-wt and c-wt (synt) and a-wt C9, c-wt C9, c-C9
up and c-C9
dw C9-tagged
chemokines expressed from SFV-vectors in BHK cells. Cell lysates (L) or culture supernatants (S) were separated by SDS-PAGE and probed with 6E9
mAb and a HRP-sheep anti-mouse Ig secondary antibody. MW, molecular weight in KDalton. Results are representative of two independent
determinations. (C) Expression of Cxcl12a and Cxcl12c mRNAs by RT-PCR in different adult mouse tissues. b-actin was used as loading control. RT +/2
denotes presence or absence of RT enzyme. Data are representative of three independent determinations. (D) Detection of CXCL12 isoforms either
with K15C mAb or anti-c-wt 6E9 mAb in mouse and human tissues. (i) Mouse adult heart. LA, left auricle; LV, left ventricle; RV, right ventricle; IVS,
interventricular septum; ca, carotid artery; mv, mitral valve. (ii) Detail of a lung bronchiol (mouse E16.5 embryo). (iii) Mouse E16.5 embryo intestin and
bladder. White arrowheads, bladder epithelium; black arrowheads, large intestine; arrows, peritoneum. In inset, details of intestinal mucosa labeling.
(iv) Large abdominal vessel (mouse E16.5 embryo). (v) Human inflammatory synovial tissue (rheumatoid arthritis). White arrowheads, blood vessel;
black arrowheads, lining synoviocytes; arrows, fibroblasts. Control: secondary antibody. Original magnifications 64 (i,iii inset),610 (iii),620 (iv), 640
(ii) and 6400 (v). (E). CXCL12 expression in the mouse bone marrow. Left panel, expression of Cxcl12a (a) and Cxcl12c (c) mRNAs determined by
quantitative real time-PCR and normalized to Gapdh expression. Results are representative from three independent determinations for each PCR
reaction. Right panel, detection of CXCL12 isoforms by use of either K15C or anti-c-wt 6E9 mAb. Control: secondary antibody. Original magnification
(640).
doi:10.1371/journal.pone.0002543.g001
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amount and nature of negatively charged structures that
contribute to CXCL12 binding in both cell types. Interestingly,
a recombinant CXCL12c derivative carrying K24S and K27S
substitutions (c-K2427Sr) that invalidate the HS-binding consen-
sus site located in the core of the protein [25] (Figure 3B) also
exhibits a reduced capacity to bind on HMVEC cells as compared
to the corresponding c-wtr protein. In keeping with these results,
the c-m2 was virtually devoid of any binding capacity on both cell
types. The specificity of CXCL12c binding to GAG was assessed
in mutant CHO-pgsD677 cells, derived from CHO-K1 cells,
which lack both N-acetylglucosaminyltransferase and glucuronyl-
transferase activities and are deficient for HS synthesis, the binding
of c-m1 became undetectable, whereas a residual signal was still
detectable for c-wt (Figure 3A), and at a similar extent for the c-
K2427Sr (data not shown). Comparable phenomena were
observed in CHO-pgsA745 cells, which lack any GAG synthesis
due to a xylose-transferase mutation. The residual binding of c-wt
(or c-K2427Sr) observed at high concentrations of the chemokine
(250 nM), in the absence of any synthesized GAG, can be
accounted for by the interaction of the C-ter domain with other
negatively charged structures, like the abundant sulphate glyco-
sphingolipids (sulphatides) that have been previously shown to
interact at high concentrations with a-wt [32]. The enzymatic
degradation of HS in CHO-K1 cells either by heparinase or
heparitinase I confirmed the apparent selectiveness of the HS/c-
wt interaction at the cell surface, whereas degradation of
chondroitin sulfate had no effect (Figure S1).
Collectively these results demonstrate the hypothesis that both
the protein core and C-ter HS-binding sites collaborate to provide
CXCL12c with the characteristic and unchallenged, high affinity
binding for GAG, and prove the validity of this assumption in cell
models of biological relevance.
Neosynthesized c-wt shows an unusual pattern of cell
secretion and accumulation
For ease of detection, the sequence coding for a 9 amino acid C-
ter (C9-tag) peptide from bovine rhodopsin that has been
satisfactorily used for tagging a large number of unrelated
proteins, was added in frame at the 39 end of the open reading
frames (ORF) of the Cxcl12a- and Cxcl12c-encoding constructs,
giving rise to the a-wt C9 and c-wt C9 proteins, respectively.
Chemokines were expressed in BHK cells by infection with
Semliki forest virus (SFV) particles expressing the corresponding
C9-tagged isoform. We observed that, upon expression, the c-wt
C9 protein was hardly detectable by western blot analysis in the
BHK cell culture supernatants (Figures 1B and 4D). This finding
prompted us to investigate the fate of this protein and to compare
it to that of a-wt C9 which was engineered and expressed under
identical experimental conditions (Figure 4A). Quantification in an
ELISA assay showed that similar amounts of c-wt C9 and a-wt C9
were produced from expressing cells (Figure 4B). Moreover,
quantification of either cell-associated (cell lysate) or free
chemokines (supernatant) reveled that a larger fraction of c-wt
C9 remained associated to cells as compared to a-wt C9. To
further investigate the distribution of the chemokine fraction
Figure 2. Immobilized GAG-binding activity of c-wt. (A) Sequence alignment of CXCL12c wt (c-wt), mutated derivatives chemokines (c-m1 and
c-m2) and mutant CXCL12c C-ter peptides (C-Ter c-m1 and C-Ter c-m2). In bold, identified and putative HS-binding motifs; underlined, substituted
amino acids. (B) Binding to HP-affinity columns of chemically synthesized wt (a-wt, c-wt) or mutant (a-m, c-m1, c-m2) chemokines or peptides
encompassing amino acids 69 to 98 of CXCL12c wt (C-ter c-wt) or their mutated derivatives (C-ter c-m1, C-ter c-m2). Proteins were applied to heparin
Hitrap-columns and eluted with a 0.15 to 1 M NaCl gradient. Values correspond to the NaCl molar (M) concentration required for elution from the
heparin column and represent three independent experiments. (C) Binding of a-wt, c-wt, c-m1 or c-m2 to on chip-immobilized heparin (HP).
Chemokines were injected over HP activated surface for 5 min, after which running buffer was injected, and the response in relative units (RU) was
recorded as a function of time. Each set of sensorgrams was obtained with a-wt at (from top to bottom) 200 to 0 nM or c-wt, c-m1 and c-m2 at 25 to
0 nM. Results are representative of three independent determinations.
doi:10.1371/journal.pone.0002543.g002
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C9-expressing cells using the anti-C9 1D4 mAb (Figure 4C).
Interestingly, c-wt C9 markedly amassed at the cell surface in
contrast to a-wt C9 (Figure 4C right panel), while in the presence
of Brefeldin A, similar amounts of each chemokine accumulated in
intracellular stores (Figure 4C left panel). Enzymatic exposure to
heparitinase I reduced the intensity of the signal for both
chemokines (data not shown), which is in full agreement with
the previous SPR data showing that c-wt binds with exceptionally
high affinity to on-chip immobilized HS (Figure 2C) and the
results obtained from the enzymatic treatment of CHO-K1 cells
(Figure S1). These findings led us to postulate that given the
cationic nature of the C-ter of c-wt and its high affinity for GAG,
electrostatic forces enable this chemokine to bind tightly to
negatively charged structures at the cell surface. This assumption
was tested by shortly exposing SFV-infected BHK cells expressing
either c-wt C9 or a-wt C9 to isotonic PBS or 1 M NaCl solution,
in order to disrupt the electrostatic interactions and eventually
promote release of the chemokine into the fluid (Figure 4D). Cell
viability of NaCl-treated cells was not altered as compared to this
of control cells (data not shown) when assessed by blue-trypan dye
exclusion. While a-wt C9-expressing cells did not release
detectable amounts of this isoform in the wash fluid (Figure 4D
lanes 3–4), a significant amount of c-wt C9 was released upon
short exposure of cells to 1 M NaCl solution (Figure 4D lane 9).
These findings were reproduced in other cell types (HEK 293T)
and with different expression vectors (pcDNA3.1).
c-wt displays reduced agonist potency on CXCR4
activation as compared to a-wt
The pharmacological properties of c-wt regarding its interaction
with CXCR4 were investigated on transformed A3.01 T cells and
primary unstimulated CD4+ T lymphocytes (Figure 5). Both
lymphoid cell types lack detectable levels of HS as assessed by
immunostaining with the specific 10E4 anti-HS mAb (data not
shown) and permits the strict analysis of CXCL12/CXCR4
interaction per se. The capacity of c-wt to set in motion CXCR4-
dependent activation cell pathways was first assessed by measuring
the amount of the non-hydrolysable [S
35]-GTPc associated to
activated Ga subunits, the earliest cell-signal event induced by
GPCR agonists. We observed that c-wt was less potent than a-wt
to activate CXCR4 (Figure 5A), which is in full agreement with
the reduced binding affinity (one order of magnitude) shown by c-
wt for CXCR4 as compared to a-wt [28]. When concentration of
c-wt was raised and the occupancy of CXCR4 was enhanced, G
protein activation increased to levels comparable to those
measured with a-wt. However, presumably due to the sustained
reduced potency of c-wt to induce GTPcS binding, we were
unable ro reach saturation for c-wt, thus precluding determination
of Emax and EC50 values for this chemokine in ths assay. For a-wt
isoform, we deduced an EC50 value equal to 19.65 nM.
CXCL12a has been shown to bind to- and activates CXCR7
[3,4,33]. We thus analysed the ability of c-wt to compete with a C-
ter biotinylated CXCL12a chemokine for binding to CXCR7. As
shown in Figure S2, a-wt and c-wt isoforms similarly bound to
Figure 3. Cell surface GAG-binding activity of a-wt and c-wt. (A) Parental (K1) or GAG-mutant (pgsD677, pgsA745) CHO cells were incubated
with the indicated concentration of wt (a-wt, c-wt) or mutant (c-m1, c-m2) chemokines for 60 min at 4uC, and after extensive washing to remove free
chemokine, were labelled with K15C mAb and a PE-goat anti-mouse Ig secondary antibody. Fixed cells were analyzed by flow cytometry. Values
represent the mean fluorescence intensity6SD of three independent experiments performed in triplicate (B) Primary human-microvascular
endothelial cells (HMVEC) were incubated with the indicated concentration of chemically synthesized (a-wt, a-m, c-wt, c-m1, c-m2; left) or
recombinant (c-wtr, c-K2427Sr, c-m1r, right) chemokines and treated as in (A). Values represent the mean fluorescence intensity6SD of two
independent experiments performed in triplicate. *p,0.05, **p,0.01, ***p,0.005 as compared to the binding obtained for the corresponding
concentration of c-wt (for c-m1 and c-m2) or c-wtr (for c-k2427Sr and c-m1r) chemokines.
doi:10.1371/journal.pone.0002543.g003
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respectively).
We next investigated the capacity of c-wt to promote CXCR4-
mediated lymphocyte migration, the hallmark of chemokine-
promoted responses (Figure 5B). Addition of c-wt to A3.01 cells
(upper panel) or primary CD4+ T lymphocytes (lower panel)
confirmed, in agreement with previous findings [33], the reduced
potencyofc-wtas compared to a-wtregardingchemotactic activity.
Addition of the specific CXCR4 antagonist AMD3100 resulted in
the blockade of both G-protein coupling and cell migration, thus
proving the specificity of CXCR4/c-wt interactions (Figure S3).
Invalidation of the C-ter BBXB motifs in c-wt (c-m1 and c-m2)
restored the potency of the chemokine to the levels showed by a-wt
and a-m, two chemokines that have been previously shown to bind
to and activate CXCR4 similarly [31]. Comparable results were
found regarding GTPcS binding, as the c-m1 mutant proved to be
consistently a better agonist than c-wt, displaying a similar potency
than this observed for a-wt (data not shown). Additionally, these
findings indicated that the mutations introduced in the C-ter
domain did not affect the overall structure of the chemokine. The
biological relevance of these results was further confirmed in
human blood leukocytes activated with phytohemagglutinin and
IL-2, a process known to enhance GAG expression on primary
cells [34] (Figure S4).
In vivo biological activity of c-wt
The singular structural and functional features that distinguish
c-wt from a-wt prompted us to compare their respective capacities
to promote haptotactic attraction of cells in vivo using chemokine
concentrations in the range of these that consistently induce
chemotaxis in vitro. To this purpose, we first evaluated the
migration of leukocytes into the peritoneal cavity of BALB/c mice
following administration of an endotoxin-free, 30 nM solution, of
c-wt or a-wt at 6 hours (hr) (Figure 6A) or 15 hr (Figure 6B) post-
injection. After 6 hr of treatment, both a-wt and c-wt induced a
significant and equivalent increase of the absolute number of cells
(fold increase 2.9960.18 and 360.18, for a-wt and c-wt
respectively, as compared to control PBS injected animals), that
was accounted for by the recruitment of myeloid cells, including
both neutrophils and macrophages (Gr-1+CD11b+CD19-,
6.2761.45 for a-wt and 8.7264.95 for c-wt). The situation was
radically different at 15 hr post-injection as solely c-wt promoted a
sustained accumulation of leukocytes (fold increase 4.9661.35 as
compared to PBS-injected animals). At this time point, cell
increase was basically accounted for by T lymphocytes (CD3+,
4.3861.65) and B lymphocytes corresponding to B1
(CD19+CD11b+, 5.0962.16) and B2 (CD19+CD11b-, 3.961)
subpopulations. Importantly, both a-m and c-m2, that totally lack
HS-binding activity, failed to attract leukocytes either at 6 hr or
15 hr time points.
CXCL12a has the capacity to promote de novo formation of
vessels, a property related to the ability of this chemokine to
regulate both the traffic and survival of stem and progenitor cells
[19,35]. Thus, we compared the ability of c-wt and a-wt to attract
endothelial progenitors and initiate the angiogenic process. To this
purpose, Matrigel plugs loaded with an endotoxin-free, 10 nM
Figure 4. Electrophoretic mobility and secretion pattern of c-wt and a-wt chemokines. (A) For detection of CXCL12 proteins by
immunoblot, SFV-infected BHK cell lysates were separated by SDS-PAGE and probed with the K15C mAb and a HRP-sheep anti-mouse Ig secondary
antibody. Abbreviations like in Fig. 1B. Formation of dimeric forms are observed for a-wt synt, a-wt C9, c-wt synt and c-wt C9. Results are
representative of three independent determinations. (B) ELISA quantification of a-wt C9 and c-wt C9 expressed by HEK-293T cells transfected with
the corresponding pcDNA3.1 expression vector. Total protein or chemokine accumulated in the cell supernatant (S) or in the cell lysates (L) were
determined. The values (ng/ml) are mean6SD from triplicate measurements. **p,0.005, ***p,0.0005. (C) The secreted c-wt C9 protein revealed by
the anti-C9 1D4 mAb accumulates massively at the cell surface of HEK-293T cells treated like in (B), and permeabilised (left panel) or not (right panel)
with saponin. In inset, cell surface CXCR4 expression of HEK-293T cells. Results are representative of four independent determinations. (D) The c-wt
C9 chemokine is released from intact cells upon exposure to strong ionic force. BHK cells were infected with SFV-infectious particles driving the
expression either of a-wt C9 or c-wt C9. Thereafter, the proteins were detected by western blot analysis using the anti-C9 1D4 mAb in the cell culture
supernatant (S), the wash fluid (WF) or the cell lysate (L), upon a 5 min exposure of cells either to PBS or hypertonic NaCl 1 M (NaCl). Results are
representative of four independent determinations.
doi:10.1371/journal.pone.0002543.g004
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BALB/c mice. Whereas virtually no infiltrating cells were
detectable in control PBS Matrigel plugs (data not shown), c-wt
induced a more robust response (3-fold increase, p=0.0009
Figure 7A) than a-wt regarding the total number of cells attracted
at day 10 post-implantation. Vessel-like cellular tubes within
Matrigel implants were particularly abundant in c-wt-loaded
implants. These vessel-like structures were mainly composed of
endothelial cells expressing CD31/Platelet endothelial cell adhe-
sion molecule (PECAM-1) (Figure 7B), a molecule that defines
endothelial cells. Similar results were observed 6 days post-
implantation, the minimal time-point required to observe
angiogenesis using this technique [36] (p=0.0459, Figure 7A
table). Of note, both a-m and c-m2 display a reduced capacity to
promote cell infiltration and angiogenesis in Matrigel implants,
demonstrating the importance of GAG binding for this process.
Discussion
Cxcl12c mRNA has been primarily detected in the central
nervous system of adult rats, where this isoform is supposed to
undergo inverse regulation as compared to the b isoform both
during brain development and in pathophysiological events like
sciatic nerve lesion [26]. Cxcl12c mRNA is also differentially
expressed in normal and myocardial infarcted rat heart [37], in
normal and ischemic brain of mice [38], and is broadly detected in
human adult tissues [27]. Here, we have characterized for the first
time the expression of CXCL12c at the protein level. The
apparent exclusion of both Cxcl12c mRNA and protein from
discrete places suggests that the expression of this isoform is tightly
regulated by a RNA-splicing regulatory mechanism. Remarkably,
CXCL12c seems to be expressed in anatomical sites, such as small
vessels and lower respiratory tract, where it could be involved in
the diapedesis of inflammatory leukocytes and other cells from
hematopoietic origin. In embryo, its enhanced capacity to form
haptotactic gradients could be critical for guiding discrete cell
precursors into their final localization during organogenesis.
The tight array of BBXB motifs in the CXCL12c C-ter domain,
that distinguish this protein from other CXCL12 isoforms, is
unprecedented among HS-binding proteins. The C-ter domain
has on its own a marked affinity for heparin that decreases
dramatically when HS-binding motifs are mutated. This observa-
tion is in keeping with our results issued from a Nuclear Magnetic
Resonance analysis of the soluble form of this chemokine [28],
which revealed that the C-ter peptide is unfolded and could offer
an accessible, highly cationic surface for the molecular recognition
in the interaction with GAG. Our interpretation of SPR findings is
that the high affinity for the oligosaccharide displayed by c-wt
largely relies in the low koff of the HP/c-wt complexes which has
been estimated to be 0.0019 M
21 s
21, contrasting with the rapid
dissociation from HP observed for a-wt (koff 0.111 M
21 s
21)[28].
This is well exemplified by the SPR profile obtained with the
mutant c-m1. This mutant dissociates more rapidly from HP and
shows a marked, reduced interaction with HP as compared to the
wild type counterpart. However, it retains a substantial affinity for
HP that might result from the stabilization of the complex through
the collaboration between the conserved BBXB motif in the core
of the chemokine and the remaining positive charges in the yet
highly cationic C-ter domain. Collectively, these data underline
the important contribution of the C-ter BBXB motifs to the
formation of high-affinity and stable HP/c-wt complexes.
The chemokine-binding experiments carried out in intact cells
proved the specificity and high affinity of c-wt for cellular HS
structures, thus validating the biological relevance of the in vitro
Figure 5. Cell signalling through CXCR4 induced either by a-wt,
c-wt or derivative chemokines. (A) CXCL12-induced [
35S]GTPcS
binding to membranes from lymphoblastoid A3.01 T cells. Membranes
were incubated in assay buffer containing 0.1 nM [
35S]GTPcS and the
indicated concentrations of the corresponding chemokine. Data
represents the percentage (mean6SD) of the maximal [
35S]GTPcS
binding obtained (100%), and are representative of three independent
experiments. (B) Dose-dependent CXCL12-induced chemotaxis of A3.01
cells (upper panel) or primary CD4+ T lymphocytes (lower panel).
Results (mean6SD) are from two independent experiments and are
expressed as percentage of input cells that migrated to the lower
chamber.
doi:10.1371/journal.pone.0002543.g005
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was also observed in an alternative assay. Indeed, our findings
prove that c-wt is massively adsorbed at the cell surface following
secretion. The simplest explanation for this phenomenon is that
the secreted c-wt could be rapidly trapped on cell-surface HS
structures. Alternatively, the high affinity of c-wt for HS might
result in the formation of an intracellular complex before being
expressed at the cell surface, a phenomenon previously described
for the Fibroblast Growth Factor-2 [39]. On view of the low
dissociation rate of HS-c-wt complexes, it can be speculated that
the secreted, free form of the chemokine hardly would reach the
equilibrium of interaction with immobilized HS and that under
physiological conditions, the binding of natural CXCL12c to
extracellular HS structures is tight and long-lasting.
Using lymphoid T cells, we confirm that c-wt signals through
CXCR4 with diminished agonist potency as compared to a-wt.
This can be accounted for by the decreased affinity of c-wt for
CXCR4 that was previously reported [28]. It can be hypothesized
that, either the electrostatic interactions of the highly cationic C-
ter domain with the negatively charged N-ter domain and
extracellular loops of CXCR4 [40], or the steric hindrance
promoted by the bulky basic residues in the c-wt C-ter domain,
impair the specific interaction with CXCR4 and therefore reduce
the agonist potency of c-wt.
Importantly, neutralization of positive charges in the BBXB motifs
of c-wt (c-m1 and c-m2) leads to an increased affinity for [28] and
activation of CXCR4 comparable to this achieved either by a-wt or
a-m, two proteins that preserves similar overstructure and efficiency
towards CXCR4 [31]. Collectively, these findings conclusively
identify the charged C-ter domain as responsible for the distinctive
structural and cell-signaling properties showed by c-wt. In contrast to
the situation observed for CXCR4, c-wt binding to CXCR7 is
comparableto this of a-wt, suggesting that molecular determinants of
CXCL12 for binding to CXCR4 and CXCR7 are different.
The demonstration of in vivo consequences of chemokine/GAG
interactions have been hampered by conformational changes
consecutive to the mutagenesis of BBXB consensus sites that leads
frequently to an overall reduced affinity of the chemokine for the
corresponding receptor [22]. The naturally occurring CXCL12c
protein is free of this bias and offers an unprecedented opportunity
to ascertain the importance of chemokine/GAG complexing in the
regulation of in vivo cell migration in adult life.
The capacity of endogenous CXCL12a to promote leukocyte
attraction in the peritoneum has been proved previously [41].
Similarly, it has been demonstrated that the formation of vessels
under physiological [19] and pathological conditions [35] is
induced by CXCL12a and is related to the regulation of the traffic
and survival of CD34+ progenitor cells. The secreted signalling
protein Vascular Endothelial Growth Factor-A (VEGF-A) is
another potent and specific angiogenic factor [42]. Vegf-A isoforms
are produced by alternative splicing from a single gene [43] and
their levels are exquisitely regulated through transcriptional
control and mRNA stability [44]. Similarly to CXCL12, these
isoforms differ by the absence or presence of protein domains that
confer the ability to bind heparin and therefore could mediate
their capacity to interact differentially with GAG components in
the extracellular environment of VEGF-secreting cells [45]. In
keeping with this assumption, it has been shown that the absence
of the heparin-binding isoforms of VEGF-A alters the distribution
and gradients of VEGF-A protein without heparin-binding
capacity in tissues and leads to a reduced vascular branching
complexity and increased microvessel calibre [46]. This situation is
reminiscent of our observation showing that c-wt displays an
enhanced capacity to induce in vivo recruitment of cells as
compared to a-wt, which is due to its enhanced affinity for HS.
This conclusion is strongly supported by the fact that the HS-
binding disabled mutant c-m2 is devoid of detectable activity in
vivo despite it shows full agonist potency on CXCR4 in vitro.
It has been shown that the association of HS with CXCL12a
prevents the proteolytic attack of its N-ter domain by the
endopeptidase CD26/DPP, thus preserving the functionality of
the chemokine [23]. CXCL12c encodes several serine-protease
Figure 6. Intraperitoneal recruitment of leukocytes induced by a-wt and c-wt. BALB/c mice were intraperitoneally injected with identical
volumes (300 ml) of either PBS (control) or a 30 nM solution of each chemokine. Cells that accumulated into the peritoneal cavity were recovered after
6 hr (A) or 15 hr (B) of treatment. Leukocyte subpopulations were characterized by flow cytometry using specific cell markers. Cell influx was
calculated as the x-fold increase over values obtained in PBS-treated mice. PBS reference values were arbitrary set to one (dotted lines). In inset, total
number of recovered peritoneal cells. Results are mean6SD of three independent experiments. *p,0.05, **p,0.01, ***p,0.005 as compared to PBS-
treated mice.
doi:10.1371/journal.pone.0002543.g006
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VEGF-A [47], the interaction of c-wt with HS also protects this
domain from proteolytic attack, thus contributing to the prolonged
immobilization and increased half-life of CXCL12c in tissues.
Overall, from our findings, we conclude that, despite its reduced
agonist potency on CXCR4, both the prolonged immobilization
and increased stability of c-wt would determine the superior
capacity of this isoform to promote chemotaxis in vivo as compared
to a-wt.
The conserved structure and differential expression of
CXCL12c both during development and in homeostatic and
pathological conditions in the adult, herald the important and
specific role that it might play both in embryogenesis and in adult
life. Its localization in vascular endothelia where leukocyte
diapedesis occurs and pathogen host defense are initiated, suggests
that this chemokine is key in the fine-tuning of immune responses.
CXCL12c would represent the paradigm of haptotactic proteins
that critically promote the directional migration and tissue homing
of cells and regulate important homeostatic and physiopatholog-
ical functions.
Materials and Methods
Chemokine synthesis and monoclonal antibodies
Chemically synthesized peptides and chemokines were gener-
ated by the Merrifield solid-phase method, and evaluated for their
purity and concentration by mass spectrometry and amino-acid
hydrolysis, respectively, as described [31]. The endotoxin content
of the protein stocks (100 mM) was determined using a highly
sensitive Limulus test (Limulus Amebocyte Lysate kit, Cambrex).
Recombinant, wild type (c-wtr) or mutant (c-m1r and c-K2427Sr)
CXCL12c chemokines were also obtained from E. coli BL21 cells
by using the pET17b expression vector, analysed by mass
spectrometry and quantified by amino acids analysis as described
[28]. The 6E9 mAb (IgG1k) directed against the wild type
CXCL12c protein was generated by immunizing BALB/c mice
with a linear peptide containing the last 30 amino-acids of the c-wt
mature isoform, as previously described [31]. The mAb clone
K15C was generated against an N-ter peptide shared by all the
CXCL12 isoforms [31].
Heparin affinity chromatography and SPR-based binding
assays
Heparin affinity chromatography of chemokines was performed
as previously described [48] on a 1-ml Hitrap heparin column and
submitted to gradient elution from 0.15 to 1 M NaCl in 20 mM
Na2HPO4/NaH2PO4. For SPR experiments, size defined HP
(6 kDa) was biotinylated at its reducing end and immobilized on a
Biacore sensorchip as described [48]. For binding assays, 250 mlo f
chemokine solution (26, 39, 59, 89, 133 or 200 nM for a-wt and
3.3, 4.9, 7.4, 11, 16.6 and 25 for c-wt, c-m1 and c-m2) was
injected at a flow rate of 50 ml/min across control and HP
surfaces, after which the formed complexes were washed with
running buffer for 5 min. The sensorchip surface was regenerated
with a 3 minutes pulse of 2 M NaCl. Control sensorgrams were
subtracted on line from HP sensorgrams. Equilibrium data were
extracted from the sensorgrams at the end of each injection and
Kd were calculated using the Scatchard representation.
Cloning of Cxcl12 isoforms
Brain tissue was obtained by dissection of a BALB/c adult
mouse. Total RNA was obtained by using the Trizol reagent
(Roche, Basel, Switzerland) and after phenol-chloroform purifica-
tion, isopropanol precipitation and quantization, cDNA was
synthesized using 1 mg of total RNA. Cxcl12a, b and c cDNA
sequences were amplified using the common forward primer
59atattgcgcgcatggacgccaaggtcgtcgcc39 and the isoform specific
reverse primers 59tacctggagaaagctttaaacaagtaagggcccaatat39 for
Cxcl12a,5 9gctttaaacaagaggctcaagatgtgagggcccaatat39 for Cxcl12b,
and 59cgacagaagaagagaaaggctgcccagaaaaggaaaaactaggggcccaa-
tat39 for Cxcl12c. Amplified sequences were subcloned in a
pcDNA3.1 expression vector or in a plasmid containing the SFV
genome deleted for structural genes (pSFV-1). For ease of
detection, the sequence coding for the bovine rhodopsin C9-tag
(TETSQVAPA) was added in frame at the 39 end of the open
reading frames (ORF) of the Cxcl12a- and Cxcl12c-encoding
constructs, giving rise to the a-wt C9 and c-wt C9 proteins,
respectively. Nucleotide substitution (serine-coding triplets) in the
Cxcl12c-C9 construct corresponding to K78/K80 or R86/K88
gave origin to the c-C9
up and c-C9
dw proteins, respectively.
Expression of Cxcl12 isoforms
Production of defective SFV particles and infections were
performed as described [49]. pcDNA3.1 constructs were trans-
fected in HEK-293T cells by the calcium phosphate method.
Figure 7. Angiogenic effect of a-wt or c-wt and derivatives
chemokines. (A) Haematoxylin-eosin staining of Matrigel plugs
containing 10 nM of the indicated chemokine and analyzed at day 10
from implantation in BALB/c mice. Data are representative of ten
independent experiments. In frame, vessel-like structures forming
arround a central lumen. In the table, quantification of the number of
migrated cells (6SD) into the Matrigel after 6 (p=0.0459) or ten days
(p=0.0009) from implantation. (B) Immunofluorescent detection of
PECAM-1/CD31
+ endothelial cells in Matrigel neovessels with DAPI
nuclear counter-labelling. Original magnifications 6100 (A) and 6600
(B).
doi:10.1371/journal.pone.0002543.g007
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transfected cells were collected and cleared by centrifugation. For
preparing cell lysates, cells were detached in PBS-EDTA,
centrifuged and pellets were treated with lysis buffer (20 mM Tris
pH 7.5, 100 mM (NH4)2 SO4, 10% Glycerol, 16 protease
inhibitor and 1% Triton X-100) and thereafter, cleared by
centrifugation. In some experiments, cells were washed for
5 minutes at 4uC with PBS or 1 M NaCl solution prior to cell
lysis and centrifuged before collecting wash fluids.
RT-PCR
Total cDNA from tissues was obtained as described above. The
PCR reaction was carried out using the forward primer 59tgcccttca-
gattgttgcac39, common for all isoforms, and the isoform specific
reverse primers 59gctaactggttagggtaatac39,5 9cttgagcctcttgtttaa39,
and 59gctagcttacaaagcgccagagcagagcgcactgcg39 for Cxcl12a,
Cxcl12b and Cxcl12c, respectively. b-actin, amplified using the
forward 59acactgtgcccatctagcagggg39 and reverse 59atgatggagtt-
gaaggtagtttcgtggat39 primers, was used as a loading control.
Quantitative real time-PCR was performed in Mx3005Tm
QPCR System with a MxPro QPCR Software 3.00 (Stratagene,
La Jolla, CA) and SYBR Green detection system. Forward and
reverse primer pairs, designed using online Primer3 software
Primer3input (primer3 www. Cgi v 0.2), were 59cttcatccc-
cattctcctca39 and 59gactctgctctggtggaagg39 for Cxcl12a and 59
cgctttgtaactcgctcctc39 and 59 cagggccttatgaagcacat39 for Cxcl12c.
No amplification was observed in PCR control reactions
containing only water as the template. The Livak method was
used to analyze the relative quantification RT-PCR data.
Immunoblotting
For immunoblotting analysis, samples were separated on 4–
12% SDS-PAGE (Bio-Rad, Hercules, CA), transferred to Filter
type PDVF sequencing membrane (Millipore, Billerica, MA) and
probed either with the anti-C9 (1D4), K15C or 6E9 mAb. A HRP-
sheep anti-mouse Ig was used as secondary antibody (Amersham,
Buckinghamshire, UK). Immunodetection was visualized using a
Super Signal West Pico chemiluminescent substrate Kit (PIERCE,
Rockford, IL) and a Fujifim LAS-1000 apparatus.
Immunohistochemistry
Paraffin-embedded, mouse tissue sections were deparaffinized and
rehydrated through graded alcohols, rinsed with PBS, blocked with a
TENG-T solution, and incubated overnight at 4uCw i t hp r i m a r y
K15C,6E9mAb orbufferalone(control).Sectionswerethenwashed
and incubated with an anti-IgG mouse alkaline phosphatase (1/200)
for 1.5 hr. Immunostaining was revealed using NBT/BCIP as
substrate. Human tissue immunostaining was revealed with an anti-
IgG mouse biotinylated antibody and avidin-peroxidase system.
Images were acquired using a Nikon Eclipse 80i microscope and a
Nikon Digital Sight DS-L camera and software.
Immunofluorescence detection of CXCL12c
HEK-293T cells were transfected by the calcium phosphate
method with 500 ng of the corresponding pcDNA3.1 expression
construct, using the pcDNA3.1 insertless vector as a control and
thereafter, cells were spread on polylysine-treated coverslips.
Immunofluorescence was performed 48 hr after transfection. To
promote intracellular accumulation of CXCL12, cells were treated
with Brefeldin A (10 mg/ml) for the last 4 hr of culture. Cells were
washed and fixed with 3.7% paraformaldehyde in PBS, permea-
bilized with PBS 0.2% BSA, 0.05% Saponine buffer for 30 min at
4uC, incubated with the 6E9 mAb for 30 min at 4uC, and finally
incubated with Texas Red anti-mouse IgG secondary antibody
(Vector Laboratories, Burlingame, CA). Images were taken using
an inverted microscope Zeiss Axiovert 200 M piloted by Zeiss
Axiovision 4.4 software and acquired with a CCD camera Roper
Scientific Coolsnap HQ and analysed using the AxioVision LE
program.
Flow cytometry analysis
CXCL12 binding to cells. Adherent HEK-293T cells,
Human Microvascular Endothelial Cells (HMVEC), parental
CHO-K1 cells, HS-deficient CHO-pgsD677 or GAG-deficient
CHO-pgsA745 mutant cells were incubated with the indicated
concentration of chemokine for 60 min at 4uC. Unbound
chemokine was removed by washing and cell-bound chemokine
was detected with the K15C mAb. After washing, cells were stained
with a PE-goat anti-mouse Ig secondary antibody (BD Pharmingen,
San Jose, CA), fixed in 3% formaldehyde buffer and analyzed by
flow cytometry (FACSscan, Becton Dickinson, CA). Statistical
analyses of the differences in binding between the wild type proteins
and their mutant counterparts were conducted using the Prism 5.0
software by fitting an unpaired two-tailed Student’s t test.
CXCL12c-C9 and CXCL12a-C9 distribution. Adherent
HEK-293T cells were transfected with the corresponding
pCDNA3.1 construct by the calcium phosphate method and
cultured for 48 hr. Four hours before collecting them, the cell
supernatants were removed and, when indicated, Brefeldin A was
added to the fresh medium. Collected cells were left untreated or
permeabilised with saponin and immunolabelled with the 1D4
mAb and a PE-goat anti-mouse Ig secondary antibody and
analysed by flow cytometry. CXCR4 detection was performed
using the PE-mouse anti-human CD184 (clone 12G5, all from BD
Bioscience).
Enzyme-linked immunosorbent assay.
Quantification of chemokines was carried out using the DuoSet
ELISA Development kit for mouse CXCL12 (R&D Systems, MN,
USA). Statistical analyses were conducted using the Prism 5.0
software by fitting an unpaired two-tailed Student’s t test.
Functional assays
For G-protein activation assay, preparation of crude membrane
fractions and [
35S]GTcS binding were performed as described
[50]. Data were analysed using non-linear regression applied to a
sigmoidal dose-response model (variable slope) with the Prism 5.0
program (GraphPad Software Inc., San Diego, CA). For
chemotaxis, freshly isolated CD4+ cells were obtained as described
previously [51]. Migration of the lymphoblastoid cell line A3.01 or
human primary CD4+ cells in response to CXCL12 was evaluated
using a transwell system as described [52].
Intraperitoneal recruitment assay
Two-month-old female BALB/c mice were intraperitoneally
injected either with PBS alone (control) or the corresponding
chemokine diluted in 300 ml of PBS at a concentration of 30 nM.
Cells were recovered by washing the peritoneum with 20 ml of
sterile PBS. Total number of cells per mouse was determined by
trypan blue exclusion and they were phenotyped by flow
cytometry analysis using the mAbs FITC-rat anti-mouse Gr-1,
FITC-hamster anti-mouse CD3, PE-rat anti-mouse CD11b or
APC-rat anti-mouse CD19 (all from BD Biosciences). Statistical
analyses and model fitting of the effect of the wild type proteins
and their mutant counterparts were conducted using the Prism 5.0
software by fitting an unpaired two-tailed Student’s t test.
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Mouse subcutaneous Matrigel implants (BD Biosciences) were
used as described [53]. Briefly, 500 ml of Matrigel containing
10 nM concentration of chemokines were subcutaneously injected
in the back skin of female 2-mo-old BALB/c mice. The major
component of Matrigel is laminin, followed by collagen IV,
heparan sulfate proteoglycans, and entactin [54]. After 6 or 10
days, skin containing Matrigel plugs were excised. Frozen sections
were fixed in 4% paraformaldehyde and analysed by haematox-
ylin-eosin staining or immunofluorescent labeling with an anti-
CD31/PECAM-1 mAb (Santa Cruz, Ca, USA). Quantitative data
were obtained by counting the number of cells (DAPI positive
nuclei) per Matrigel area in digitalised images using ImageJ
software (http://rsb.info.nih.gov/ij). Images were taken in a Zeiss
Axioplan 2 microscope (Carl Zeiss, Jena , Germany) using a
SpotRT CCD camera and Spot 4.5 software (Diagnostic
Instruments, Sterling Heights , MI). Statistical analysis was
conducted by fitting an unpaired two-tailed Student’s t test, as
described above.
Supporting Information
Figure S1 Comparative GAG-binding activity of a-wt and c-wt
on parental CHO-K1 cells. Prior to incubation with the proteins,
cells were treated with 10-3 units/mL of Heparinase (25uC),
Heparitinase I (37uC) or Chondroitinase ABC (37uC) degrading
enzymes (Seikagaku corporation, Tokyo, Japan) for 90 minutes.
Cells were washed twice with PBS, detached with 2 mM EDTA in
PBS and then assayed for CXCL12 binding as described
previously (flow cytometry analysis). Binding to control untreated
cells were arbitrary set to 100 and binding observed for enzyme-
treated cells was expressed as a function of signal obtained in
control conditions. Data are the mean6SD from three indepen-
dent determinations. In inset, HS detection at the cell surface of
control (K1) or Heparitinase I treated (K1+HT) CHO parental
cells was performed using mouse IgM isotype control (gray-filled
histogram) or the anti-HS mAb clone 10E4 and a PE-goat anti-
mouse Ig secondary antibody.
Found at: doi:10.1371/journal.pone.0002543.s001 (1.59 MB TIF)
Figure S2 CXCR7 is a high affinity receptor for both a-wt and
c-wt. (A) Specific CXCL12 a-CXCR7 interaction. 0.5 nM a-biot
was added to A0.01 parental cells (Parental) or CXCR7-
transduced A0.01 cells (CXCR7) and revealed by flow cytometry
after addition of the streptavidin (SAv)-PE conjugate antibody (BD
Bioscience) at 1 mg/ml. When indicated, a-biot binding to
CXCR7 was inhibited using the mouse anti-human CXCR7
mAb (9C4, 50 mg/ml) or the a-wt chemokine (1 mM). Binding of
SAv-PE alone to parental cells was arbitrary set to 1. (B)
Concentration-dependent inhibition of 1 nM a-biot binding to
CXCR7-transduced A0.01 cells by untagged a-wt or c-wt
chemokines. Cells were incubated with the indicated concentra-
tion of the chemokines, and after washing, labeled with 1 mg/ml of
SAv-PE and analyzed by flow cytometry. Results are normalized
for specific binding performed in the absence of competitor (100%,
untreated). Binding parameters were determined with the Prism
Software using non-linear regressions applied to one-site models.
Results (mean6SD) are representative out of two (A) or three (B)
independent experiments performed in duplicate.
Found at: doi:10.1371/journal.pone.0002543.s002 (1.57 MB TIF)
Figure S3 AMD3100 effect in CXCL12-induced signalling. (A)
[35S]GTPcS binding assay to membranes from lymphoblastoid
A3.01 T cells upon activation with increasing concentrations of a-
wt or c-wt chemokines. When indicated 200 nM of AMD3100
was added to the incubation mix. Data are mean6SD of triplicate
determinations from two independents experiments. (B) Chemo-
taxis of A3.01 cells. Chemokines were added to the lower chamber
at a concentration of 3 nM for a-wt and 10 nM for c-wt to obtain
the maximal chemotactic effect for these cells. When indicated,
AMD3100 was added to the upper and lower chamber at a final
concentration of 200 nM. Results (mean6SD) are from two
independent experiments and are expressed as percentage of input
cells that migrated to the lower chamber.
Found at: doi:10.1371/journal.pone.0002543.s003 (1.08 MB
DOC)
Figure S4 Chemotactic activities of CXCL12 isoforms in
activated leukocytes. (A) Primary lymphocytes blasted with
phytohemagglutinin and expanded with IL-2 were left untreated
or treated with Heparitinase I+Chondroitinase ABC (HT+CH)
and incubated with the indicated concentrations of chemokine for
60 min at 4{degree sign}C. After extensive washing to remove
unbound chemokine, cells were labelled with the K15C mAb and
a PE-goat anti-mouse Ig secondary antibody. Fixed cells were
analyzed by flow cytometry. Values represent the mean fluores-
cence intensity6SD of three independent experiments performed
in triplicate. (B) Dose-dependent a-wt- or c-wt-induced chemo-
taxis assessed in untreated and HT+CH-treated, activated primary
lymphocytes. Results (mean6SD) are from two independent
experiments and are expressed as percentage of input cells that
migrated to the lower chamber.
Found at: doi:10.1371/journal.pone.0002543.s004 (1.33 MB TIF)
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